European approval procedure for the six-month dosage of Eligard successfully completed

Published: 4-Sep-2007
Regulatory Drug Delivery Pharmaceutical

The European approval procedure for the six-month dosage of Eligard has been successfully completed, paving the way for the launch of this dosage of the drug for the treatment of prostate cancer in Europe.


The European approval procedure for the six-month dosage of Eligard has been successfully completed, paving the way for the launch of this dosage of the drug for the treatment of prostate cancer in Europe.

After subcutaneous injection of this dosage, the drug is released steadily over a period of six months. Eligard is the only six-month depot product of a drug against prostate cancer available in Europe. The one-month and three-month products have been available in all major European countries.

MediGene acquired the licence for pan-European commercialisation of Eligard from the US company Atrix Laboratories in April 2001, and successfully took the drug through the approval procedure, first of all in Germany, and afterwards, in co-operation with Astellas in Europe. Eligard has been marketed in Europe by MediGene's licensee Astellas Pharma Europe since May 2004.

The six-month dosage was launched in Germany in March 2007. Other available formulations include the one-month and three-month depot products.

"There has been tremendous response since the launch of the Eligard six-month formulation earlier this year in Germany," said Dr Peter Heinrich, ceo of MediGene. "We are now glad that we can offer this dosage to patients across Europe."

  • Companies:
  • Astellas Pharma
See more

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

Read more
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  3. Lessons learned: AstraZeneca’s supply chain resilience during the pandemic With 26 manufacturing facilities and a global network of more than 250 suppliers, AstraZeneca’s Global Operations Manufacturing footprint is not only large in scale, it's also highly complex and positioned to deliver medicines to patients worldwide
  4. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Regulatory

Padcev plus Keytruda approved for advanced urothelial cancer by the EC

The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Research & Development

Astellas invests $13m in cell and gene therapy innovation incubators

Japanese Astellas’ nearly $13m will make it a Founding Sponsor of LabCentral's new incubator with a core lab space for process development studies and a non-GMP pilot plant
Finance

Astellas to buy Ocata Therapeutics

New step forward in ophthalmology and stem cell therapy
Research & Development

Astellas and Anokion to collaborate on immune tolerance therapeutics

The creation of a new company, Kanyos, will enable the preclinical development of products for type 1 diabetes and coeliac disease
Regulatory

Antifungal agent – isavuconazole

A new antifungal agent has been granted fast-track status by the FDA, as well as being designated a qualified infectious disease product, and an orphan drug for invasive aspergillosis and mucormycosis
Subscribe now